FDA makes historic ruling on biosimilar insulin

Patients taking Sanofi's long-acting insulin Lantus can now access Mylan's copy drug Semglee.

Photo: Andrew Kelly/REUTERS / X02844

On Thursday evening, the US Food and Drug Administration (FDA) ruled that a biosimilar drug is interchangeable with the original. It is the first time ever that the agency has done this.

For patients using Sanofi's long-acting insulin Lantus, this means that they will now be able to get Mylan's product Semglee from their pharmacist, without having a doctor's prescription for that specific drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs